366 reports of this reaction
2.0% of all BRENTUXIMAB VEDOTIN reports
#11 most reported adverse reaction
THROMBOCYTOPENIA is the #11 most commonly reported adverse reaction for BRENTUXIMAB VEDOTIN, manufactured by SEAGEN INC.. There are 366 FDA adverse event reports linking BRENTUXIMAB VEDOTIN to THROMBOCYTOPENIA. This represents approximately 2.0% of all 18,008 adverse event reports for this drug.
Patients taking BRENTUXIMAB VEDOTIN who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is a less commonly reported adverse event for BRENTUXIMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to thrombocytopenia, the following adverse reactions have been reported for BRENTUXIMAB VEDOTIN:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 366 FDA reports for BRENTUXIMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 2.0% of all adverse event reports for BRENTUXIMAB VEDOTIN, making it a notable side effect.
If you experience thrombocytopenia while taking BRENTUXIMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.